Lumipulse® p-tau217/Beta-Amyloid 42 Ratio, Plasma
- Laboratory
- Quest Diagnostics
- Test code
- 17970
- Specimen
- Plasma
- Fasting
- Not stated
- LOINC
- 104663-0, 33200-7
- Turnaround
- Set up: Mon-Sat
Laboratory assay overview
AD-Detect™ p-tau217/Beta-Amyloid 1-42 Ratio, Plasma (FDA Cleared) is cleared by the FDA for assessment of patients aged >=50 years with signs or symptoms of cognitive decline. The levels of two proteins, p-tau217 and Beta-amyloid 1-42, are evaluated within the plasma and calculated into an analytical ratio. This ratio is correlated to the presence or absence of amyloid plaques in the patient's brain, which may reduce the need for an amyloid-PET scan.
Quest Diagnostics population reference ranges
Quest Diagnostics calculates these statistical intervals for this specific assay and demographic group, not as universal optimal targets.
| Population | Range |
|---|---|
| ptau217 | Not Established |
| ABeta 42 | Not Established |
| ptau217/ABeta 42 Ratio | ≤0.00370 |
| Lower Risk | ≤0.00370 |
| Indeterminate Risk | 0.00371-0.00737 |
| Higher Risk | ≥0.00738 |
View complete laboratory reference notes
ptau217 | Not Established ABeta 42 | Not Established ptau217/ABeta 42 Ratio | ≤0.00370 Plasma p-tau217/ABeta 42 ratio Risk Table Lower Risk | ≤0.00370 Indeterminate Risk | 0.00371-0.00737 Higher Risk | ≥0.00738 The Lumipulse G pTau 217/Beta-Amyloid 1-42 Plasma Ratio results must be interpreted in conjunction with other patient clinical information.
Quest Diagnostics test directory, test code 17970